Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vacucis Candida autovaccine for chronic oral candidiasis (phase 2, randomized triple-blind)
2022-001210-19Phase 2Active
- Sponsor
- Abel García García
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in oral candidiasis comparing Vacucis Candida autovaccine with Placebo (2 arms). Primary endpoint: Prevalence and severity of candidiasis. Started Apr 2022; status: active.
02
Drugs
Vacucis
03
Conditions
oral candidiasis
Beyond the preview
Go deeper on 2022-001210-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001210-19.